Assessment of the Neutralizing Antibody Response of BNT162b2 and mRNA-1273 SARS-CoV-2 Vaccines in Naïve and Previously Infected Individuals: A Comparative Study
View/ Open
Date
2022-02-01Author
Shurrab, Farah M.Al-Sadeq, Duaa W.
Abou-Saleh, Haissam
Al-Dewik, Nader
Elsharafi, Amira E.
Hamaydeh, Fatima M.
Abo Halawa, Bushra Y.
Jamaleddin, Tala M.
Abdul Hameed, Huda M.
Nizamuddin, Parveen B.
Amanullah, Fathima Humaira
Daas, Hanin I.
Abu-Raddad, Laith J.
Nasrallah, Gheyath K.
...show more authors ...show less authors
Metadata
Show full item recordAbstract
The currently authorized mRNA COVID-19 vaccines, Pfizer-BNT162b2 and Moderna-mRNA-1273, offer great promise for reducing the spread of the COVID-19 by generating protective immunity against SARS-CoV-2. Recently, it was shown that the magnitude of the neutralizing antibody (NAbs) response correlates with the degree of protection. However, the difference between the immune response in naïve mRNA-vaccinated and previously infected (PI) individuals is not well studied. We investigated the level of NAbs in naïve and PI individuals after 1 to 26 (median = 6) weeks of the second dose of BNT162b2 or mRNA-1273 vaccination. The naïve mRNA-1273 vaccinated group (n = 68) generated significantly higher (~2-fold, p ≤ 0.001) NAbs than the naïve BNT162b2 (n = 358) group. The P -vaccinated group (n = 42) generated significantly higher (~3-fold; p ≤ 0.001) NAbs levels than the naïve-BNT162b2 (n = 426). Additionally, the older age groups produced a significantly higher levels of antibodies than the young age group (>30) (p = 0.0007). Our results showed that mRNA-1273 generated a higher NAbs response than the BNT162b2 vaccine, and the PI group generated the highest level of NAbs response regardless of the type of vaccine.
Collections
- Biological & Environmental Sciences [915 items ]
- Biomedical Research Center Research [735 items ]
- Biomedical Sciences [720 items ]
- COVID-19 Research [822 items ]
- Dental Medicine Research [294 items ]
- Medicine Research [1448 items ]